• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

    6/24/25 7:00:00 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVIR alert in real time by email

    C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada

    Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect

    HCV Infection Remains a Significant Global Health Burden, with Approximately 50 Million People Infected, Including up to 4 Million in US

    BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that the first patient was dosed in the global Phase 3 C-FORWARD trial evaluating the combination regimen of bemnifosbuvir and ruzasvir compared to the regimen of sofosbuvir and velpatasvir for the treatment of hepatitis C virus (HCV). C-FORWARD, the second of two Phase 3 trials comparing this regimen, is being conducted at study sites outside of North America. Atea initiated C-BEYOND, the Company's Phase 3 trial in the US and Canada in April 2025 and continues to enroll patients in that study. In both studies, the regimen of bemnifosbuvir and ruzasvir is being administered orally once-daily for 8 weeks (in patients without cirrhosis) or 12 weeks (in patients with compensated cirrhosis) while the regimen of sofosbuvir and velpatasvir is being administered orally once-daily for 12 weeks.

    "We are pleased to reach another important milestone for our global HCV program with the first patient dosed in C-FORWARD, our HCV Phase 3 trial being conducted outside North America. Our Phase 3 program is now enrolling patients on a global basis," said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and founder of Atea. "We are focused on the successful development of a potential best-in-class HCV regimen that may make it easier to treat and cure patients infected with HCV. The target profile of our regimen is particularly well suited for both patients and healthcare providers in test-to-treat models of care, which enables seamless diagnosis and treatment for patients infected with HCV."

    HCV continues to be a significant global health burden despite the availability of direct-acting antivirals, with an estimated 50 million people worldwide chronically infected with HCV, and approximately one million new infections each year. It is estimated that between 2.4 to 4 million people in the US alone are living with chronic HCV. 

    "It has been nearly a decade since the last generation of treatments for HCV became available to patients and in this time, the patient population and what they need to obtain a cure has evolved. Many patients infected with HCV are taking concomitant medications, including some that may not be recommended with the currently available HCV therapies," said Dr. Eric Lawitz, MD, The Texas Liver Institute, Clinical Professor of Medicine, University of Texas Health San Antonio. "The regimen of bemnifosbuvir and ruzasvir may offer a potent and more convenient option for my patients and may also make treatment more accessible for any patient who tests positive for HCV. I look forward to seeing the Phase 3 results when they are available."

    "The evolving HCV patient population and rising burden of untreated HCV in Europe mirrors trends seen in North America. Many patients present with co-morbidities and complex medical histories, with treatment decisions often influenced by concomitant medications," said Tarik Asselah, MD, PhD, a principal investigator in the C-FORWARD trial and a Professor of Hepatology, Hôpital Beaujon, Assistance Publique–Hôpitaux de Paris (AP-HP), University of Paris-Cité, France. "To truly advance HCV eradication and meet the needs of today's patients, an ideal treatment would combine high efficacy, short duration, and minimal risk of drug-drug interactions."

    Atea hosted a virtual HCV panel discussion with key opinion leaders (KOLs) on May 14, 2025. A panel of six experts, including leading hepatologists and prescribers from the US, Canada and Europe, discussed the current challenges for patients infected with HCV and the results from Atea's global Phase 2 study evaluating the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor were reviewed. Company management also reviewed the HCV commercial market opportunity and the design for the global Phase 3 clinical development program. To listen to the replay of the KOL event, please click here.

    About the Phase 3 C-BEYOND and C-FORWARD Trials in Adults with Chronic HCV

    Atea is conducting two open-label Phase 3 trials, C-BEYOND in the US and Canada, and C-FORWARD, a global trial outside of North America. Each Phase 3 trial is expected to enroll approximately 880 treatment-naïve patients, including those with and without compensated cirrhosis. The trials are comparing the fixed dose combination (FDC) regimen of bemnifosbuvir and ruzasvir to the FDC regimen of sofosbuvir and velpatasvir. The regimen of bemnifosbuvir and ruzasvir is being administered orally once-daily for 8 weeks (in patients without cirrhosis) or 12 weeks (in patients with compensated cirrhosis) while the regimen of sofosbuvir and velpatasvir is being administered orally once-daily for 12 weeks for all patients with or without compensated cirrhosis.

    The primary endpoint for each trial is HCV RNA < lower limit of quantitation (LLOQ) at 24 weeks from the start of treatment and encompasses sustained virologic response 12 weeks post-treatment (SVR12) in each arm. Measurement at 24 weeks from the start of treatment is to ensure the primary endpoint occurs at the same relative timepoint from the start of treatment in all patients.

    Last month, at the European Association for the Study of the Liver (EASL) Congress 2025, Atea presented results from the full cohort of patients (n=275) enrolled in its Phase 2 study evaluating the regimen. These results showed a robust 98% (210/215) SVR12 with the regimen in the "Per-Protocol Treatment-Adherent Population." The SVR12 rate was 95% (245/259) in the "Per-Protocol Regardless of Adherence Population" (also referred to as the "efficacy evaluable population"), which included patients who were not treatment adherent (17%).

    Results from three additional Phase 1 studies demonstrated that the combination of bemnifosbuvir and ruzasvir had a low risk of drug-drug interactions (DDIs) and supported the safety of the regimen in HCV patients co-infected with human immunodeficiency virus (HIV) taking a standard HIV treatment, and the safety of bemnifosbuvir in participants with hepatic or renal impairment with no need for dose adjustments.

    About HCV

    HCV is a blood-borne, positive-sense, single-stranded (ss) RNA virus that primarily infects liver cells. A leading cause of chronic liver disease and liver transplants, HCV is mainly spread via blood transfusion, hemodialysis and needle sticks, with 242,000 deaths occurring each year. Chronic HCV infection is the leading cause of liver cancer in the US, Europe and Japan.

    In the US, HCV infections predominate in patients in the age group between 20-49 years old, and it is estimated that fewer than approximately 10% of patients have cirrhosis.

    About Bemnifosbuvir and Ruzasvir for HCV

    Bemnifosbuvir has been shown in in vitro studies to be approximately 10-fold more active than sofosbuvir (SOF) against a panel of laboratory strains and clinical isolates of HCV GT 1–5. In vitro studies have also demonstrated bemnifosbuvir remained fully active against SOF resistance-associated substitutions (S282T), with up to 58-fold more potency than SOF. The pharmacokinetic (PK) profile of bemnifosbuvir supports once-daily dosing for the treatment of HCV. In both nonclinical and clinical studies, bemnifosbuvir has been shown to have a low risk for DDIs. Bemnifosbuvir has been administered to over 2,300 subjects and has been well-tolerated at doses up to 550 mg for durations up to 12 weeks in healthy subjects and patients.

    Ruzasvir has demonstrated highly potent and pan-genotypic antiviral activity in preclinical (picomolar range) and clinical studies. Ruzasvir has been administered to over 2,100 subjects at daily doses of up to 180 mg for 12 weeks and has demonstrated a favorable safety profile. The PK profile of ruzasvir supports once-daily dosing.

    About Atea Pharmaceuticals

    Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea's deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Atea's lead program and current focus is on the development of the combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, to treat HCV. For more information, please visit www.ateapharma.com.

    Forward Looking Statement

    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to statements regarding the potential best-in-class profile of the regimen of bemnifosbuvir and ruzasvir for the treatment of HCV and the potential to develop a regimen that makes it easier to treat and cure HCV patients. When used herein, words including "expected," "should," "anticipated," "believe," "will," "plans", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Atea's current expectations and various assumptions. Atea believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Atea may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, uncertainties inherent in the drug discovery and development process and the regulatory submission or approval process, unexpected or unfavorable safety or efficacy data or results observed during clinical trials or in data readouts; delays in or disruptions to clinical trials or our business; our reliance on third parties over which we may not always have full control, our ability to manufacture sufficient commercial product, competition from approved treatments for HCV, the timeline for the completion of the strategic alternatives review process is unknown and there can be no assurance that the process will result in any particular outcome; dependence on the success of Atea's most advanced product candidates, in particular the combination of bemnifosbuvir and ruzasvir for the treatment of HCV; as well as the other important factors discussed under the caption "Risk Factors" in Atea's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC's website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While Atea may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing Atea's views as of any date subsequent to the date of this press release.

    Contacts

    Jonae Barnes

    SVP, Investor Relations and Corporate Communications

    617-818-2985

    [email protected]

    Joyce Allaire

    LifeSci Advisors

    [email protected]



    Primary Logo

    Get the next $AVIR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AVIR

    DatePrice TargetRatingAnalyst
    8/13/2024$2.00 → $6.88Underweight → Equal-Weight
    Morgan Stanley
    8/10/2023Neutral → Underweight
    JP Morgan
    3/2/2022$10.00 → $8.00Neutral
    JP Morgan
    3/1/2022$10.00 → $9.00Market Perform
    SVB Leerink
    2/16/2022$11.00 → $10.00Market Perform
    SVB Leerink
    1/6/2022$14.00 → $7.00Equal-Weight → Underweight
    Morgan Stanley
    11/18/2021Outperform → Mkt Perform
    SVB Leerink
    11/18/2021$11.00Outperform → Market Perform
    SVB Leerink
    More analyst ratings

    $AVIR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Atea Pharmaceuticals upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Atea Pharmaceuticals from Underweight to Equal-Weight and set a new price target of $6.88 from $2.00 previously

      8/13/24 7:25:26 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals downgraded by JP Morgan

      JP Morgan downgraded Atea Pharmaceuticals from Neutral to Underweight

      8/10/23 6:17:18 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan reiterated coverage on Atea Pharmaceuticals with a new price target

      JP Morgan reiterated coverage of Atea Pharmaceuticals with a rating of Neutral and set a new price target of $8.00 from $10.00 previously

      3/2/22 10:09:39 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVIR
    SEC Filings

    See more
    • SEC Form 8-K filed by Atea Pharmaceuticals Inc.

      8-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)

      6/20/25 5:16:20 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Atea Pharmaceuticals Inc.

      SCHEDULE 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

      5/14/25 6:21:56 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Atea Pharmaceuticals Inc.

      10-Q - Atea Pharmaceuticals, Inc. (0001593899) (Filer)

      5/12/25 4:45:23 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVIR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Berger Franklin M converted options into 29,600 shares, increasing direct ownership by 6% to 506,497 units (SEC Form 4)

      4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      6/24/25 6:05:09 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Duncan Barbara Gayle converted options into 29,600 shares, increasing direct ownership by 89% to 62,750 units (SEC Form 4)

      4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      6/24/25 6:05:09 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Murphy Polly A. converted options into 29,600 shares, increasing direct ownership by 52% to 86,045 units (SEC Form 4)

      4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      6/24/25 6:05:11 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVIR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Berger Franklin M bought $81,498 worth of shares (25,000 units at $3.26), increasing direct ownership by 6% to 476,897 units (SEC Form 4)

      4/A - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      1/17/25 2:30:36 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Berger Franklin M decreased direct ownership by 1% to 476,897 units (SEC Form 4)

      4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      1/17/25 8:03:19 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVIR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

      C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect HCV Infection Remains a Significant Global Health Burden, with Approximately 50 Million People Infected, Including up to 4 Million in US BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, t

      6/24/25 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Supporting Potential Best-in-Class Profile Presented at European Association for the Study of the Liver (EASL) Congress 2025 Virtual Investor Event with Key Opinion Leader Insights on HCV to be Held May 14, 2025, at 10:00 AM ET BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results fo

      5/12/25 4:11:14 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025

              Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for Regimen Results from Phase 1 Study Showed Low Risk for Drug-Drug Interactions with Regimen When Co-Administered with Standard HIV Treatment Regimen Bemnifosbuvir Was Generally Safe and Well Tolerated with No Dose Adjustment Neededin Phase 1 Studies in Participants with Hepatic or Renal Impairment Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 BOSTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the d

      5/7/25 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVIR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc.

      SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

      11/15/24 10:34:54 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc.

      SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

      11/12/24 9:50:14 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

      2/15/24 11:35:08 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVIR
    Financials

    Live finance-specific insights

    See more
    • Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Supporting Potential Best-in-Class Profile Presented at European Association for the Study of the Liver (EASL) Congress 2025 Virtual Investor Event with Key Opinion Leader Insights on HCV to be Held May 14, 2025, at 10:00 AM ET BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results fo

      5/12/25 4:11:14 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

      Panel to Discuss Current Challenges Encountered by Patients with HCV, Results from Atea's Phase 2 Study of the Regimen of Bemnifosbuvir and Ruzasvir, and What a New Optimized HCV Therapy Could Provide for Prescribers and Patients Event to Replace Atea's First Quarter 2025 Earnings Conference Call; Quarterly Calls to Resume with Second Quarter 2025 Financial Results BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea" or "Company"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced it will virtually host a hepatitis C virus (HCV) key opi

      5/1/25 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus (HCV) Patient Enrollment in Global Phase 3 HCV Program Expected to Start in April 2025 Conference Call at 4:30 pm ET Today BOSTON, March 06, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. "I am pleased to share that we recently had a successful End-of-Phase 2 meeting with

      3/6/25 4:05:00 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVIR
    Leadership Updates

    Live Leadership Updates

    See more
    • Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

      BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea" or "Company"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Howard H. Berman, Ph.D. to its Board of Directors (the "Board"). Dr. Berman will serve as a non-voting observer to the Board through Atea's 2025 Annual Meeting of Stockholders when he will join the Board as a full voting member. "We are pleased to welcome Howard Berman to the Atea Board," said Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and Founder of Atea. "We look forward to benefitting from

      4/17/25 7:00:00 AM ET
      $AVIR
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

      BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

      2/24/25 7:00:00 AM ET
      $AVIR
      $LQDA
      $KDMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Atea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development

      BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for severe viral diseases, today announced the appointment of Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development. Dr. Agrawal previously served as Vice President of Pharmacokinetics, Pharmacodynamics, and Drug Metabolism at Merck & Co., Inc. "We are delighted to welcome Nancy to the Atea team. Her broad scientific and managerial experience in both drug discovery and drug development spanning across multiple therapeutic areas at Merck, will enrich our scientific and c

      2/10/22 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care